Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Benmelstobart vs Chemotherapy in pMMR Endometrial Cancer
NCT06475599Phase 3Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib, benmelstobart in endometrial cancer (EC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06475599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475599.